Acetylisovaleryl tylosin tartrate antibody/antigen (BSA/OVA/KLH conjugated hapten)

anti-Acetylisovaleryl tylosin tartrate antibody and Carrier-coupled antigen/immunogen (hapten-carrier conjugates)

Target products collectionGo to Antibiotics diagnostics products collection >>


Product information

Catalog No.DescriptionUS $ Price (per mg)
GMP-SMT-30-11. BSA-Acetylisovaleryl tylosin tartrate
2. Anti-Acetylisovaleryl tylosin tartrate mouse monoclonal antibody
$2709.00
GMP-SMT-30-21. OVA-Acetylisovaleryl tylosin tartrate
2. Anti-Acetylisovaleryl tylosin tartrate mouse monoclonal antibody
$2709.00
GMP-SMT-30-31. BSA-Acetylisovaleryl tylosin tartrate
2. Anti-Acetylisovaleryl tylosin tartrate human monoclonal antibody
$2709.00
GMP-SMT-30-41. OVA-Acetylisovaleryl tylosin tartrate
2. Anti-Acetylisovaleryl tylosin tartrate human monoclonal antibody
$2709.00
GMP-SMT-30-Ag-1BSA-Acetylisovaleryl tylosin tartrate$756.00
GMP-SMT-30-Ag-2OVA-Acetylisovaleryl tylosin tartrate$756.00
GMP-SMT-30-Ab-1Anti-Acetylisovaleryl tylosin tartrate mouse monoclonal antibody$1953.00
GMP-SMT-30-Ab-2Anti-Acetylisovaleryl tylosin tartrate human monoclonal antibody$1953.00

Size: 1mg | 10mg | 100mg



Product Description


BSA-Acetylisovaleryl tylosin tartrate

Cat No.GMP-SMT-30-Ag-1
Bioactivity validationCompetitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;
Products descriptionCompetitive immunoassay-validated hapten-carrier conjugates BSA-Acetylisovaleryl tylosin tartrate with anti-Hapten antibody. The hapten hapten-carrier conjugates BSA-Acetylisovaleryl tylosin tartrate had been validated with our anti-Hapten antibody Anti-Acetylisovaleryl tylosin tartrate mouse monoclonal antibody via competitive ELISA test.
ApplicationELISA tests and other immunoassays;
Lateral flow immunoassay (LFIA);
LTIA
Immunonephelometry
Time-resolved Fluorescence Immunoassay (TRFIA)
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


OVA-Acetylisovaleryl tylosin tartrate

Cat No.GMP-SMT-30-Ag-2
Bioactivity validationCompetitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;
Products descriptionCompetitive immunoassay-validated hapten-carrier conjugates OVA-Acetylisovaleryl tylosin tartrate with anti-Hapten antibody. The hapten hapten-carrier conjugates OVA-Acetylisovaleryl tylosin tartrate had been validated with our anti-Hapten antibody Anti-Acetylisovaleryl tylosin tartrate mouse monoclonal antibody via competitive ELISA test.
ApplicationELISA tests and other immunoassays;
Lateral flow immunoassay (LFIA);
LTIA
Immunonephelometry
Time-resolved Fluorescence Immunoassay (TRFIA)
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Anti-Acetylisovaleryl tylosin tartrate mouse monoclonal antibody

Cat No.GMP-SMT-30-Ab-1
Host of AntibodyMouse IgG
Bioactivity validationCompetitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;
Lateral flow immunoassay (LFIA);
ELISA IC50 (ppb)10.00
Products descriptionThe anti-Hapten antibody against hapten Acetylisovaleryl tylosin tartrate had been validated with our hapten hapten-carrier conjugates BSA-Acetylisovaleryl tylosin tartrate via competitive ELISA test.
ApplicationELISA tests and other immunoassays;
Lateral flow immunoassay (LFIA);
LTIA
Immunonephelometry
Time-resolved Fluorescence Immunoassay (TRFIA)
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Anti-Acetylisovaleryl tylosin tartrate human monoclonal antibody

Cat No.GMP-SMT-30-Ab-2
Host of AntibodyHuman IgG1
Bioactivity validationCompetitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;
Lateral flow immunoassay (LFIA);
ELISA IC50 (ppb)10.00
Products descriptionThe anti-Hapten antibody against hapten Acetylisovaleryl tylosin tartrate had been validated with our hapten hapten-carrier conjugates BSA-Acetylisovaleryl tylosin tartrate via competitive ELISA test.
ApplicationELISA tests and other immunoassays;
Lateral flow immunoassay (LFIA);
LTIA
Immunonephelometry
Time-resolved Fluorescence Immunoassay (TRFIA)
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Biomarker Information


    1.Pirlimycin (PIR) in Veterinary Drug Residues and Additives

    Pirlimycin (PIR) is a critical antibiotic belonging to the lincosamide class, renowned for its vital role in veterinary medicine. Its primary application is in the treatment of bacterial infections in animals, especially in the dairy industry. One of its most significant applications is in the management of mastitis, an inflammatory condition of the mammary gland in dairy cows, often caused by bacterial infections. PIR has proven to be an invaluable tool in mitigating the detrimental effects of mastitis on milk production and quality.

    In the context of veterinary drug residues and additives, Pirlimycin demands thorough examination. This scrutiny is imperative due to the potential for residual presence in animal-derived products like milk and meat. Neglecting the monitoring of Pirlimycin residues could result in contamination of these products, thereby posing risks to public health and disrupting the integrity of the food supply chain. Regulatory authorities enact stringent guidelines and limits to govern Pirlimycin residues, reinforcing the need for vigilant measurement.

    2.Importance of Measuring Pirlimycin (PIR)

    The measurement of Pirlimycin (PIR) levels is underscored by several compelling rationales:

    a. Ensuring Food Safety and Regulatory Adherence: The regular assessment of Pirlimycin residues is fundamental in guaranteeing compliance with rigorous food safety regulations. This practice ensures that animal-derived products meet established safety standards and are devoid of any potentially harmful substances, assuring consumer safety.

    b. Antibiotic Stewardship: The judicious administration of antibiotics, including Pirlimycin, is pivotal in curtailing the emergence of antibiotic-resistant bacteria. Monitoring PIR levels plays a pivotal role in evaluating the prudent use of this antibiotic and encouraging antibiotic stewardship programs within veterinary practices.

    c. Enhancing Dairy Product Quality: In the dairy sector, where Pirlimycin finds extensive application, monitoring its residues is instrumental in maintaining the quality of milk and dairy products. By upholding optimal antibiotic residue levels, dairy farmers can enhance product quality and market competitiveness.

    d. Fostering Consumer Confidence: Rigorous testing and quantification of Pirlimycin residues serve to bolster consumer confidence. As consumers are assured of the absence of harmful residues in animal-derived products, their trust in the industry and the safety of their purchases is reinforced.

    3.Mechanism of Action and Veterinary Applications of Pirlimycin

    Pirlimycin exerts its antibiotic properties through inhibition of protein synthesis in bacteria. This mechanism of action disrupts the growth and proliferation of the bacterial pathogens responsible for various infections in animals, particularly dairy cows. Its excellent tissue penetration and prolonged duration of action make it a suitable choice for the treatment of mastitis, which often requires sustained antibiotic exposure for effective resolution.

    The dairy industry heavily relies on Pirlimycin for mastitis management. This disease not only reduces milk yield but also compromises milk quality. The presence of bacteria in the udder can lead to the contamination of milk with pathogens and their byproducts, impacting the safety and quality of the final dairy products, such as milk, cheese, and yogurt. Therefore, Pirlimycin's effectiveness in treating mastitis is crucial for both animal welfare and the production of safe, high-quality dairy products.

    4.Residue Concerns and Public Health

    As with any antibiotic used in veterinary medicine, there is a potential for residues of Pirlimycin to persist in animal-derived products. These residues can result from improper withdrawal periods, dosage miscalculations, or other factors. The presence of antibiotic residues in food products poses a significant risk to public health.

    Consuming food with antibiotic residues can contribute to the development of antibiotic resistance in humans. The ingestion of trace amounts of antibiotics through food can lead to the survival of antibiotic-resistant bacteria in the human gut. This can ultimately reduce the effectiveness of antibiotics in treating human infections, making it a critical concern for public health authorities and medical professionals.

    5.Regulatory Framework for Pirlimycin Residues

    To address the concerns surrounding antibiotic residues, including those of Pirlimycin, regulatory authorities in many countries have established stringent guidelines and maximum residue limits (MRLs). These MRLs specify the maximum allowable concentration of a specific antibiotic, including Pirlimycin, in animal-derived products such as meat and milk.

    The monitoring and enforcement of these MRLs are crucial for ensuring food safety and preventing the spread of antibiotic resistance. Veterinarians, farmers, and food producers must adhere to these regulations to maintain the integrity of the food supply chain and protect public health. Violations of MRLs can result in legal consequences and damage the reputation of the industry.

    6.Analytical Techniques for Pirlimycin Residue Detection

    Accurate and sensitive analytical techniques are essential for detecting and quantifying Pirlimycin residues in animal-derived products. Various methods are employed for this purpose, including:

    a. Liquid Chromatography-Mass Spectrometry (LC-MS): LC-MS is a powerful technique for the identification and quantification of Pirlimycin residues. It offers high specificity and sensitivity, making it suitable for trace-level analysis in complex matrices.

    b. Enzyme-Linked Immunosorbent Assay (ELISA): ELISA is an immunological method that uses antibodies specific to Pirlimycin to detect its presence in samples. It is a relatively quick and cost-effective method for screening purposes.

    c. Microbiological Assays: These assays use bacterial strains sensitive to Pirlimycin and can provide a qualitative assessment of its presence in samples.

    d. High-Performance Liquid Chromatography (HPLC): HPLC is a versatile technique that can be employed for Pirlimycin residue analysis when coupled with appropriate sample preparation and detection methods.

    7.Conclusion

    In conclusion, Pirlimycin (PIR) plays a crucial role in veterinary medicine, particularly in the dairy industry, for the treatment of mastitis. However, the careful monitoring of Pirlimycin residues in animal-derived products is essential to ensure food safety, promote responsible antibiotic use, maintain product quality, and bolster consumer confidence. The potential risks associated with antibiotic residues in food products, including the development of antibiotic resistance, make it imperative for regulatory authorities to establish and enforce maximum residue limits. Analytical techniques like LC-MS, ELISA, and microbiological assays are valuable tools for detecting and quantifying Pirlimycin residues, ensuring the safety and quality of our food supply. As we continue to address these concerns and refine our monitoring methods, we can strive for a safer, more responsible approach to antibiotic use in veterinary medicine.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.